What are the typical clinical features of polymyalgia rheumatica and the recommended management?

Polymyalgia Rheumatica: Presentation and Management

Clinical Presentation

Polymyalgia rheumatica (PMR) presents with bilateral shoulder and hip girdle pain accompanied by prolonged morning stiffness (typically >45 minutes) in patients over 60 years of age, with elevated inflammatory markers (ESR and CRP). 1

Key Clinical Features:

• Age: Almost exclusively affects patients >50 years, typically >60 years
• Pain distribution: Bilateral shoulder girdle pain is most common, often with neck and hip girdle involvement
• Morning stiffness: Prominent and prolonged (>45 minutes), improves with activity
• Constitutional symptoms: May include fatigue, low-grade fever, weight loss, malaise
• Laboratory findings: Elevated ESR (often >40 mm/1st hour) and CRP are typical
• Rapid response to glucocorticoids: Dramatic improvement within 2-4 weeks is characteristic and helps confirm diagnosis

Atypical Features Requiring Specialist Referral:

Consider specialist evaluation when patients present with 1:

• Peripheral inflammatory arthritis
• Systemic symptoms beyond typical PMR
• Low or normal inflammatory markers
• Age <60 years
• Lack of response to appropriate glucocorticoid therapy within 2 weeks

Management Algorithm

Initial Assessment and Diagnosis

Before initiating treatment, document a minimal clinical and laboratory dataset including inflammatory markers, assess comorbidities that increase glucocorticoid-related risks (diabetes, osteoporosis, hypertension, glaucoma, cardiovascular disease, peptic ulcer), and evaluate risk factors for relapse. 1

First-Line Treatment: Glucocorticoids

Initiate oral prednisone at 12.5-25 mg/day as monotherapy for most patients with PMR. 1

Dose Selection Within This Range:

• Higher dose (20-25 mg/day): For patients with high risk of relapse (female sex, high ESR >40 mm/1st hour, peripheral arthritis) and low risk of adverse events
• Lower dose (12.5-15 mg/day): For patients with significant comorbidities (diabetes, osteoporosis, glaucoma, hypertension, cardiovascular disease) or other glucocorticoid-related risk factors

Critical: Do NOT use initial doses ≤7.5 mg/day (insufficient efficacy) or >30 mg/day (excessive adverse events without added benefit). 1

Glucocorticoid Tapering Protocol

Expect clinical improvement within 2-4 weeks; if no improvement occurs, reconsider the diagnosis. 1

Structured Tapering Schedule:

1. Initial tapering (weeks 0-8): Reduce to 10 mg/day prednisone within 4-8 weeks
2. Maintenance tapering: Once remission achieved, taper by 1 mg every 4 weeks (or 1.25 mg decrements using alternate-day schedules like 10/7.5 mg) until discontinuation
3. Relapse management: Increase to pre-relapse dose, then decrease gradually within 4-8 weeks to the dose where relapse occurred, then resume slow taper

Monitoring Schedule

Follow patients every 4-8 weeks in the first year, every 8-12 weeks in the second year, and as needed for relapses or during final taper. 1

At each visit assess:

• Disease activity and symptoms
• Inflammatory markers (ESR, CRP)
• Glucocorticoid-related adverse events
• Comorbidity status
• Adherence and patient concerns

Adjunctive Therapy: When to Add Steroid-Sparing Agents

Consider adding methotrexate (7.5-10 mg/week orally) early in treatment for patients at high risk of relapse/prolonged therapy OR those with significant comorbidities where glucocorticoid-related adverse events are likely. 1

Specific Scenarios for Methotrexate:

• Female patients with peripheral inflammatory arthritis
• Patients with difficult-to-control diabetes, osteoporosis, or glaucoma
• Patients experiencing relapse despite appropriate glucocorticoid management
• Patients developing significant glucocorticoid-related adverse events

Note: Recent evidence supports IL-6 receptor inhibitors (tocilizumab, sarilumab) as highly effective glucocorticoid-sparing agents 2, 3, though the 2015 EULAR/ACR guidelines predate this evidence. These may be considered in refractory cases or high-risk patients in consultation with rheumatology.

Alternative Glucocorticoid Formulation

Intramuscular methylprednisolone (120 mg every 3 weeks initially) may be considered as an alternative to oral glucocorticoids, particularly in patients where lower cumulative glucocorticoid exposure is desirable (e.g., difficult-to-control hypertension, diabetes, osteoporosis). 1

However, this approach is supported by limited evidence and may not be available in all settings.

What NOT to Use

Do NOT use NSAIDs as primary treatment for PMR—they are ineffective for the underlying inflammatory process. 1 NSAIDs may be used short-term for pain related to other conditions.

Do NOT use TNF-α blocking agents—there is no evidence of benefit and considerable risk of harm. 1

Common Pitfalls and How to Avoid Them

1. Insufficient initial dose: Using <12.5 mg/day prednisone leads to inadequate disease control and diagnostic uncertainty
2. Excessive initial dose: Using >30 mg/day increases adverse events without improving outcomes
3. Too-rapid tapering: Attempting to reduce below 10 mg/day too quickly (faster than 1 mg every 4 weeks) increases relapse risk
4. Missing alternative diagnoses: If no improvement within 2 weeks at appropriate doses, strongly reconsider the diagnosis—think rheumatoid arthritis, spondyloarthritis, malignancy, infection
5. Inadequate monitoring: Failing to assess for glucocorticoid-related complications (osteoporosis, diabetes, hypertension, cataracts) leads to preventable morbidity
6. Ignoring atypical features: Peripheral arthritis, age <60, normal inflammatory markers warrant specialist evaluation to exclude mimics

Risk Factors for Poor Outcomes

Female sex, high ESR (>40 mm/1st hour), and peripheral inflammatory arthritis are associated with higher relapse rates and prolonged therapy requirements, though evidence is inconsistent. 1 These patients may benefit from higher initial doses within the recommended range and earlier consideration of methotrexate.